Inotodiol

Inotodiol activates p53 signaling pathway, inhibits MMP-2/9, and exhibits antitumor activity in cancer cell HeLa. Inotodiol inhibits the generation of ROS and exhibits antioxidant and neuroprotective effects. Inotodiol inhibits the activation of MAPK and NF-κB signaling pathway, and exhibits anti-inflammatory activity. Inotodiol inhibits TLR-4 mediated TNF-α production (IC₅₀s in BMMC and BMDM is 0.7 μM and 3.0 μM), inhibits the degranulation in mast cell, exhibits anti-allergic activity. Inotodiol is orally active^{[1][2][3][4][5]}. In Vitro: Inotodiol (0-100 μM, 72 h) inhibits the proliferation of cell HeLa, inhibits the cell migration and invasion, induces apoptosis i HeLa^[2].
Inotodiol (0.1-10 μM, 28 h) inhibits the ROS generation, activates SOD, improves oxygen and glucose deprivation-induced mitochondrial dysfunction, reduces the leakage of lactate dehydrogenase and exhibits neuroprotective effect in PC12 cell^[3].
Inotodiol (2 μg/mL, 24 h) inhibits H₂O₂-induced expression of IL-1β, IL-6, TNF-α and COX-2, and blocks the senescence in human dermal fibroblasts (HDF)^[4]. In Vivo: Inotodiol (2-20 mpk, po, once daily for 3-5 days) inhibits allergic reactions in passive systemic anaphylaxis and passive cutaneous anaphylaxis, exhibits antiasthmatic activity in mouse models^[5].